• PharmaCorp Rx posted Q2 2026 revenue of $7.7 million, up 75.8% from a year earlier.
• Net income turned to $0.12 million from a loss, helped by higher gross profit and other income.
• Non-IFRS adjusted EBITDA (pre-IFRS 16, 4-wall basis) more than doubled to $1.7 million.
• Same-store sales rose 3.8% while same-store prescription sales increased 5.2% versus Q2 2025.
• Store count climbed to 16 after post-quarter acquisitions, including eight pharmacies in Eastern Canada and deals in Ontario and Western Canada.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmacorp Rx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200730PRIMZONEFULLFEED9813321) on August 20, 2026, and is solely responsible for the information contained therein.